KINOMEscan™ announces scanLIPID Kinase Assay Panel

Feb. 5, 2009 - PRLog -- KINOMEscan™, a division of Ambit Biosciences and leader in kinase profiling services, has just expanded its service offering with the release of scanLIPID™, the largest commercial collection of human lipid kinase assays available.  Included in this panel are PI3K, PI4K, PIP, and clinically relevant mutants.  
Lipid kinases are critical to controlling cell function and regulation of biological pathways.  They have recently emerged as attractive drug targets as a growing body of evidence implicates them as key players in several disease processes including cancer.  
Coupled with KINOMEscan’s best-in-industry high-throughput kinase profiling platform, researchers are now able to rapidly profile compounds in a highly standardized assay format against the largest human lipid kinase panel available.  

For more information on scanLIPID or other assay panels available from KINOMEscan, please visit www.kinomescan.com

# # #

KINOMEscan™ provides kinase selectivity profiling for drug discovery and optimization. KINOMEscan, is the industry's most comprehensive high-throughput system for screening compounds and libraries against the world’s largest panel of human kinases.